论文部分内容阅读
[目的]比较替吉奥联合顺铂与FOLFOX4方案治疗晚期胃癌的近期疗效及不良反应。[方法]40例晚期胃癌患者随机分为两组,试验组即替吉奥联合顺铂治疗20例,对照组即FOLFOX4方案治疗20例,观察两组药物的近期疗效及不良反应。[结果]试验组CR0例,PR7例,有效率35%;对照组CR1例,PR8例,有效率45%,两组疗效无显著性差异(P>0.05)。1年生存率分别为48%、50%,中位生存期分别为10.8个月、11.7个月,两组间无显著性差异(P>0.05)。两组骨髓抑制及胃肠道反应发生率均较为常见,发生率无统计学差异。手足综合征发生率试验组明显高于对照组(P<0.05),而对照组的不良反应主要是外周神经毒性及腹泻,发生率显著高于试验组(P<0.05)。[结论]替吉奥联合顺铂治疗晚期胃癌的疗效肯定,值得临床进一步扩大研究。
[Objective] To compare the short-term curative effect and side effects of the combination of cisplatin and FOLFOX4 in the treatment of advanced gastric cancer. [Method] Forty patients with advanced gastric cancer were randomly divided into two groups. Twenty patients were treated with TIGO combined with Cisplatin in the experimental group, and 20 patients in the control group were treated with FOLFOX4 regimen. The short-term efficacy and side effects of the two drugs were observed. [Results] The CR0 cases and PR7 cases in the experimental group had an effective rate of 35%. The control group had CR1 and PR8 cases, with an effective rate of 45%. There was no significant difference between the two groups (P> 0.05). The 1-year survival rates were 48% and 50%, respectively. The median survival time was 10.8 months and 11.7 months respectively. There was no significant difference between the two groups (P> 0.05). The incidence of myelosuppression and gastrointestinal reactions were more common in both groups, with no significant difference in incidence. The incidence of hand-foot syndrome was significantly higher in the experimental group than in the control group (P <0.05), while the adverse reactions in the control group were mainly peripheral neurotoxicity and diarrhea, with a significantly higher incidence (P <0.05). [Conclusion] Treatment of advanced gastric cancer with tiotropium combined with cisplatin is effective and worth further clinical study.